SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL

羟基脲作为镰状细胞预防疗法的安全性和有效性

• 批准号: 7377385
• 负责人: Eugene P Orringer
• 金额: $ 0.17万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377385
• 关键词: SAFETY; EFFICACY; HYDROXYUREA; PROPHYLACTIC; THERAPY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this double-blind, randomized study is: a) to compare the clinical course of patients receiving hydroxyurea to a control group receiving placebo and; b) to quantitate the effect of hydroxyurea on fetal hemoglobin production in the red blood cells of patients with sickle cell anemia.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项双盲，随机研究的目的是：a）将接受羟基脲的患者与接受安慰剂的对照组进行比较； b）定量羟基脲对镰状细胞贫血患者红细胞胎儿血红蛋白产生的影响。